Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1987 1
1993 1
2008 1
2009 2
2010 2
2011 2
2013 1
2018 1
2019 1
2020 2
2021 1
2022 2
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

15 results

Results by year

Filters applied: . Clear all
Page 1
Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial.
Rummel MJ, Niederle N, Maschmeyer G, Banat GA, von Grünhagen U, Losem C, Kofahl-Krause D, Heil G, Welslau M, Balser C, Kaiser U, Weidmann E, Dürk H, Ballo H, Stauch M, Roller F, Barth J, Hoelzer D, Hinke A, Brugger W; Study group indolent Lymphomas (StiL). Rummel MJ, et al. Lancet. 2013 Apr 6;381(9873):1203-10. doi: 10.1016/S0140-6736(12)61763-2. Epub 2013 Feb 20. Lancet. 2013. PMID: 23433739 Clinical Trial.
Significantly longer time to deterioration of quality of life due to CANKADO PRO-React eHealth support in HR+ HER2- metastatic breast cancer patients receiving palbociclib and endocrine therapy: primary outcome analysis of the multicenter randomized AGO-B WSG PreCycle trial.
Harbeck N, Fasching PA, Wuerstlein R, Degenhardt T, Lüftner D, Kates RE, Schumacher J, Räth P, Hoffmann O, Lorenz R, Decker T, Reinisch M, Göhler T, Staib P, Gluz O, Schinköthe T, Schmidt M; AGO-B WSG PreCycle investigators (see Appendix 1). Harbeck N, et al. Ann Oncol. 2023 Aug;34(8):660-669. doi: 10.1016/j.annonc.2023.05.003. Epub 2023 May 16. Ann Oncol. 2023. PMID: 37201751 Free article. Clinical Trial.
Pomalidomide plus dexamethasone for patients with relapsed or refractory multiple myeloma: Final results of the non-interventional study POSEIDON and comparison with the pivotal phase 3 clinical trials.
Dechow T, Aldaoud A, Behlendorf T, Knauf W, Eschenburg H, Groschek M, Hansen R, Söling U, Grebhardt S, Siebenbach HU, Vannier C, Potthoff K. Dechow T, et al. Among authors: soling u. Eur J Haematol. 2022 Feb;108(2):133-144. doi: 10.1111/ejh.13719. Epub 2021 Nov 15. Eur J Haematol. 2022. PMID: 34714555 Free PMC article.
Comprehensive analysis of isolated der(1;7)(q10;p10) in a large international homogenous cohort of patients with myelodysplastic syndromes.
Ganster C, Müller-Thomas C, Haferlach C, Strupp C, Ogata K, Germing U, Hildebrandt B, Mallo M, Lübbert M, Müller C, Solé F, Götze KS, Vandenberghe P, Göhring G, Steinmetz T, Kröger N, Platzbecker U, Söling U, Raynaud S, Shirneshan K, Schanz J, Haase D. Ganster C, et al. Among authors: soling u. Genes Chromosomes Cancer. 2019 Oct;58(10):689-697. doi: 10.1002/gcc.22760. Epub 2019 Apr 30. Genes Chromosomes Cancer. 2019. PMID: 30994215
Effectiveness and Tolerability of Nab-paclitaxel in Younger versus Elderly Patients With Metastatic HR-positive/HER2-negative Breast Cancer: Results From the Noninterventional, Prospective Study NABUCCO.
Potthoff K, Stötzer O, Söling U, Hansen R, Harde J, Dille S, Nusch A, Marschner N. Potthoff K, et al. Among authors: soling u. Clin Breast Cancer. 2020 Jun;20(3):e315-e326. doi: 10.1016/j.clbc.2019.11.003. Epub 2020 Mar 10. Clin Breast Cancer. 2020. PMID: 32273207
Giant platelets in erucic acid therapy for adrenoleukodystrophy.
Stöckler S, Molzer B, Plecko B, Zenz W, Muntean W, Söling U, Hunneman DH, Korenke C, Hanefeld F. Stöckler S, et al. Among authors: soling u. Lancet. 1993 May 29;341(8857):1414-5. doi: 10.1016/0140-6736(93)90984-o. Lancet. 1993. PMID: 8098819 No abstract available.
Final Effectiveness and Safety Results of NABUCCO: Real-World Data From a Noninterventional, Prospective, Multicenter Study in 697 Patients With Metastatic Breast Cancer Treated With nab-Paclitaxel.
Marschner N, Salat C, Söling U, Hansen R, Grebhardt S, Harde J, Nusch A, Potthoff K. Marschner N, et al. Among authors: soling u. Clin Breast Cancer. 2018 Dec;18(6):e1323-e1337. doi: 10.1016/j.clbc.2018.07.010. Epub 2018 Aug 10. Clin Breast Cancer. 2018. PMID: 30100104 Free article.
Final results from IMPROVE: a randomized, controlled, open-label, two-arm, cross-over phase IV study to determine patients' preference for everolimus in combination with exemestane or capecitabine in combination with bevacizumab in advanced HR-positive, HER2-negative breast cancer.
Decker T, Söling U, Hahn A, Maintz C, Kurbacher CM, Vehling-Kaiser U, Sent D, Klare P, Hagen V, Chiabudini M, Falkenstein J, Indorf M, Runkel E, Potthoff K. Decker T, et al. Among authors: soling u. BMC Cancer. 2020 Apr 6;20(1):286. doi: 10.1186/s12885-020-06747-y. BMC Cancer. 2020. PMID: 32252684 Free PMC article. Clinical Trial.
First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia.
Eichhorst BF, Busch R, Stilgenbauer S, Stauch M, Bergmann MA, Ritgen M, Kranzhöfer N, Rohrberg R, Söling U, Burkhard O, Westermann A, Goede V, Schweighofer CD, Fischer K, Fink AM, Wendtner CM, Brittinger G, Döhner H, Emmerich B, Hallek M; German CLL Study Group (GCLLSG). Eichhorst BF, et al. Among authors: soling u. Blood. 2009 Oct 15;114(16):3382-91. doi: 10.1182/blood-2009-02-206185. Epub 2009 Jul 15. Blood. 2009. PMID: 19605849 Free article. Clinical Trial.
15 results